Vicriviroc is a piperazine‐based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH‐C, but …

Vicriviroc is a piperazine-based CCR5 receptor antagonist, that showed better oral
availability, potency, safety, and pharmacological properties than its precursor SCH-C, but …

A novel series of CCR5 antagonists has been identified, utilizing the lead, nifeviroc, which
were further modified based on bioisosteric principles. Lead optimization was pursued by …

Piperazinopiperidine amide analogs are among the most promising CCR5 antagonists. As
an effective extension of a previously-reported methodology to synthesize such compounds …

In this study, a series of 1, 3, 4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors
were taken as our target with the method of the three-dimensional quantitative structure …

Finding specific inhibitors for the immunodeficiency syndrome caused by virus, HIV-1 or HIV-
2 is still a difficult task. HIV most commonly uses CCR5 and CXCR4 as a co-receptor along …

The CCR5 chemokine receptor has recently been found to play a crucial role in the viral
entry stage of HIV infection and has therefore become an attractive potential target for anti …

Objective: Monocyte chemo attractant protein-1 (MCP-1) is a member of the CC-chemokine
family and it selectively recruits leukocytes from the circulation to the site of inflammation …

The discovery of chemokine receptor-5 (CCR5) antagonists for the treatment of HIV-1
infection exemplifies the success that can be achieved when possible chemical leads are …

Based on a putative 'Y shape'pharmacophore model of CCR5 inhibitors, a series of novel
piperidine-4-carboxamide derivatives were designed and synthesized using a group …